CONMED Corporation
NYSE:CNMDMedical - Devices
+$0.24 today
- Market cap
- $1.43B
- Beta
- 0.92
- P/E (TTM)
- 18.0
- EPS (TTM)
- $1.79
- Dividend yield
- 1.24%
Volume 0.36M
Average 0.45M
CNMD Net Income
Bottom-line profit, the starting point for calculating cash from operations.
CONMED CorporationNYSE: CNMD
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $13.83M rose 129.1% year over year, ahead of the -53.8% change in trailing-twelve-month net income. Sequentially, it fell 17.4% from the prior quarter.
Context
- Net income amounted to 3.4% of revenue in FY2025, down 6.7 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of $142.35M (+202.5%) for the fiscal year ending Dec 2026, a step up from the -64.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $13.83M-17.4% QoQ
- Last fiscal yearDec 2025
- $47.06M-64.5% YoY
- LTMMar 2026
- $54.85M-53.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +129.1% | +56.1% | -73.0 pp |
| 1 year | -64.5% | +202.5% | +267.0 pp |
| 3-year CAGR | — | +51.3% | — |
| 5-year CAGR | +34.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 47.06M USD
- Year-over-year change
- -64.5%
- 4-year CAGR
- -6.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 47.06M | -64.5% |
| FY2024 | 2024-12-31 | 132.42M | +105.4% |
| FY2023 | 2023-12-31 | 64.46M | +180.0% |
| FY2022 | 2022-12-31 | (80.58M) | -228.8% |
| FY2021 | 2021-12-31 | 62.54M | — |
Net Income vs competitors
How CNMD compares with its peers on the latest reported figures
- CNMD's LTM Mar 2026 net income of $54.85M is the 9th largest of the 11 companies compared; the peer median is $67.72M.
- Its year-over-year change of -53.8% is the 9th highest of 11, against a peer median of -18.9%.
- Net income amounts to 4.0% of revenue for CNMD, versus a peer median of 22.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $500.92M | -4.8% | +3.1% | 757.9% | |
| LTM Mar 2026 | $173.05M | +5.4% | +13.8% | 25.7% | |
| LTM Sep 2026 | $166.99M | +199.5% | +125.1% | 26.9% | |
| LTM Jan 2026 | $143.89M | +69.3% | — | 171.9% | |
| LTM Mar 2026 | $87.19M | -50.4% | -16.6% | 23.3% | |
| LTM Apr 2026 | $79.3M | -184.7% | — | 2.8% | |
| LTM Jun 2026 | $72.3M | +7.7% | +17.8% | 11.4% | |
| LTM Aug 2026 | $56.14M | -94.6% | -29.8% | 6.4% | |
| LTM Mar 2026 | $54.85M | -53.8% | — | 4.0% | |
| LTM Sep 2026 | $38.45M | -53.7% | -12.1% | 14.6% | |
| LTM Mar 2026 | $10.03M | -33.1% | +55.7% | 20.7% | |
| Peer median (excluding CNMD) | $67.72M | -18.9% | +8.4% | 22.0% | |
Competitors are the stored peer set for CNMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 62.54M | (80.58M) | 64.46M | 132.42M | 47.06M |
| Depreciation & Amortization | 70.74M | 69.52M | 51.4M | 51.31M | 74.28M |
| Deferred Income Tax | 3.01M | (6.04M) | 700K | 12.2M | 3.52M |
| Stock-Based Compensation | 16.34M | 21.73M | 24.26M | 25.56M | 28.32M |
| Change in Working Capital | (55.7M) | (90.7M) | (39.58M) | (39.72M) | (11.45M) |
| Accounts Receivables | (9.16M) | (5.2M) | (47.07M) | (1.62M) | (2.36M) |
| Inventory | (37.81M) | (78.56M) | 14.07M | (31.63M) | (6.73M) |
| Accounts Payables | 4.89M | 13.3M | 14.85M | 14.71M | (9.75M) |
| Other Working Capital | (13.62M) | (20.23M) | (21.43M) | (21.19M) | 7.39M |
| Other Non-Cash Items | 14.84M | 119.44M | 24.11M | (14.8M) | 28.96M |
| Operating Cash Flow | 111.77M | 33.37M | 125.35M | 166.97M | 170.69M |
| Capital Expenditures | (14.87M) | (21.79M) | (19.03M) | (13.08M) | (19.81M) |
| Acquisitions (Net) | 0 | (227.74M) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (1M) | 0 | (1.15M) |
| Investing Cash Flow | (14.87M) | (249.53M) | (20.03M) | (13.08M) | (20.96M) |
| Debt Repayment | (81.24M) | 362.02M | (88M) | (72M) | (74.59M) |
| Common Stock Issued | 0 | 72M | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (72M) | 0 | 0 | 0 |
| Dividends Paid | (23.26M) | (23.96M) | (24.5M) | (24.65M) | (24.75M) |
| Other Financing Activities | 2.95M | (113.06M) | 2.07M | (54.35M) | (36.49M) |
| Financing Cash Flow | (101.55M) | 225M | (110.43M) | (151M) | (135.82M) |
| Effect of Forex Changes | (1.87M) | (741K) | 470K | (2.72M) | 2.45M |
| Net Change in Cash | (6.51M) | 8.1M | (4.65M) | 163K | 16.36M |
| Free Cash Flow | 96.9M | 11.58M | 106.32M | 153.88M | 150.88M |
CONMED Corporation
NYSE:CNMD
Intrinsic Alpha fair value
Locked
Current Price
$48.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.